<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Kalaris Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/kalaris-therapeutics-inc</link>
<description>Latest news and press releases for Kalaris Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 17 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/kalaris-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68358e5878dffbe2df1012de.webp</url>
<title>Kalaris Therapeutics, Inc.</title>
<link>https://6ix.com/company/kalaris-therapeutics-inc</link>
</image>
<item>
<title>Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-reports-full-year-2025-financial-results-and-provides-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-reports-full-year-2025-financial-results-and-provides-business-updates</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>Positive initial data reported from Phase 1a Single Ascending Dose study in nAMD in December 2025; preliminary data from ongoing Phase 1b/2 study expected in</description>
</item>
<item>
<title>Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting</title>
<link>https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-present-phase-1-clinical-210500611</link>
<guid isPermaLink="true">https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-present-phase-1-clinical-210500611</guid>
<pubDate>Wed, 28 Jan 2026 21:05:00 GMT</pubDate>
<description>BERKELEY HEIGHTS, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company developing differentiated therapies for retinal diseases, today announced that clinical data from its Phase 1 study of TH103 will be presented at the 49th Annual Meeting of the Macula Society, taking place February 25-28 in San Diego, California. TH103 is a novel investigational therapy engineered by VEGF scientific pioneer Dr. Napoleone Ferr</description>
</item>
<item>
<title>Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement</title>
<link>https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-therapeutics-announces-oversubscribed-50-225900464</link>
<guid isPermaLink="true">https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-therapeutics-announces-oversubscribed-50-225900464</guid>
<pubDate>Wed, 17 Dec 2025 22:59:00 GMT</pubDate>
<description>BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell securities in a private placement for aggregate gross proceeds of approximately $50.0 million, before deduct</description>
</item>
<item>
<title>Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD</title>
<link>https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-therapeutics-reports-positive-initial-210100566</link>
<guid isPermaLink="true">https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-therapeutics-reports-positive-initial-210100566</guid>
<pubDate>Wed, 17 Dec 2025 21:01:00 GMT</pubDate>
<description>TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection TH103 was generally well tolerated, supporting further dose escalation beyond 2.5 mg TH103 showed a 27 to 51-fold lower plasma Cmax by pharmacokinetic analysis compared with current leading agents, indicative of increased intraocular retention Accelerating enrollment in ongoing Phase 1b/2 multi ascending dose-finding study; preliminary efficacy and safety data expecte</description>
</item>
<item>
<title>Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference</title>
<link>https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-present-noble-capital-markets-130000186</link>
<guid isPermaLink="true">https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-present-noble-capital-markets-130000186</guid>
<pubDate>Mon, 24 Nov 2025 13:00:00 GMT</pubDate>
<description>Berkeley Heights, New Jersey--(Newsfile Corp. - November 24, 2025) - Kalaris Therapeutics, Inc. (Nasdaq: KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Noble Capital Markets 21st Annual Emerging Growth Equity Conference.Details:Type: Company presentationSpeakers: Matthew Feinsod, Chief Medical Officer Date: Wednesday,...</description>
</item>
<item>
<title>Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-reports-third-quarter-2025-130000649</link>
<guid isPermaLink="true">https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-reports-third-quarter-2025-130000649</guid>
<pubDate>Wed, 12 Nov 2025 13:00:00 GMT</pubDate>
<description>Phase 1a Single Ascending Dose trial remains on track for initial clinical data to be reportedby year end 2025 Phase 1b/2 Multiple Ascending Dose trial currently enrolling, intended to inform dose selection for potential Phase 3 development program; initial clinical data expected in 2H 2026 Recent significant corporate milestones include the selection of a CDMO, CFO hire, and opening of corporate headquarters Cash, cash equivalents and short-term investments of $77.0M as of September 30, 2025, e</description>
</item>
<item>
<title>Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer</title>
<link>https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-expands-leadership-team-appointing-123000856</link>
<guid isPermaLink="true">https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-expands-leadership-team-appointing-123000856</guid>
<pubDate>Mon, 03 Nov 2025 12:30:00 GMT</pubDate>
<description>Highly experienced biopharma financial officer joins leadership team CFO hire bolsters Kalaris’ leadership team and supports continued growth of the company as it enrolls its Phase 1b/2 study in treatment naïve nAMD patients PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Matthew Gall,</description>
</item>
<item>
<title>Kalaris to Present at Stifel 2025 Annual Healthcare Conference</title>
<link>https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-present-stifel-2025-annual-120000860</link>
<guid isPermaLink="true">https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-present-stifel-2025-annual-120000860</guid>
<pubDate>Thu, 30 Oct 2025 12:00:00 GMT</pubDate>
<description>PALO ALTO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Stifel 2025 Annual Healthcare Conference. Details: Type: Company presentationSpeakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical OfficerDate: Thursday, November</description>
</item>
<item>
<title>UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration</title>
<link>https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-therapeutics-now-enrolling-phase-192600530</link>
<guid isPermaLink="true">https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-therapeutics-now-enrolling-phase-192600530</guid>
<pubDate>Mon, 15 Sep 2025 19:26:00 GMT</pubDate>
<description>Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and efficacy in nAMD patients receiving four initial monthly doses of TH103 Phase 1b/2 study to inform dose selection for potential Phase 3 development program, with initial data expected in 2H 2026 TH103’s ongoing Phase 1a single ascending dose study remains on track for data to be reported in Q4 2025 PALO ALTO, Calif., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a</description>
</item>
<item>
<title>Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration</title>
<link>https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-therapeutics-now-enrolling-phase-120000820</link>
<guid isPermaLink="true">https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-therapeutics-now-enrolling-phase-120000820</guid>
<pubDate>Mon, 15 Sep 2025 12:00:00 GMT</pubDate>
<description>Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and preliminary efficacy in nAMD patients receiving up to four initial monthly doses of TH103 Phase 1b/2 study to inform dose selection for potential Phase 3 development program, with initial data expected in 2H 2026 TH103’s ongoing Phase 1a single ascending dose study remains on track for data to be reported in Q4 2025 PALO ALTO, Calif., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KL</description>
</item>
<item>
<title>Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-reports-second-quarter-2025-120000602</link>
<guid isPermaLink="true">https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-reports-second-quarter-2025-120000602</guid>
<pubDate>Wed, 13 Aug 2025 12:00:00 GMT</pubDate>
<description>Continuing to enroll nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina; initial clinical data is expected in Q4 2025 Cash and cash equivalents of $88.4M as of June 30, 2025, expected to fund operations into Q4 2026 PALO ALTO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a cl</description>
</item>
<item>
<title>Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference</title>
<link>https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-present-noble-capital-markets-120000218</link>
<guid isPermaLink="true">https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-present-noble-capital-markets-120000218</guid>
<pubDate>Mon, 02 Jun 2025 12:00:00 GMT</pubDate>
<description>PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference. The formal presentation will feature a fireside style Q&A session with questions welcome from the live virtual audience.</description>
</item>
<item>
<title>Kalaris to Participate at Stifel Ophthalmology Forum</title>
<link>https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-participate-stifel-ophthalmology-forum-150300662</link>
<guid isPermaLink="true">https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-participate-stifel-ophthalmology-forum-150300662</guid>
<pubDate>Fri, 23 May 2025 15:03:00 GMT</pubDate>
<description>PALO ALTO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will participate at an upcoming Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum. Details: Type: Fireside ChatSpeakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical OfficerDate: Tues</description>
</item>
<item>
<title>Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights</title>
<link>https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-reports-first-quarter-2025-120000759</link>
<guid isPermaLink="true">https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-reports-first-quarter-2025-120000759</guid>
<pubDate>Wed, 14 May 2025 12:00:00 GMT</pubDate>
<description>Actively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina; initial clinical data is expected in Q4 2025 Cash and cash equivalents of $101M as of March 31, 2025, expected to fund operations into Q4 2026 PALO ALTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clini</description>
</item>
<item>
<title>Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee</title>
<link>https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-expands-board-directors-appointing-120000253</link>
<guid isPermaLink="true">https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-expands-board-directors-appointing-120000253</guid>
<pubDate>Fri, 04 Apr 2025 12:00:00 GMT</pubDate>
<description>Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase of growthPALO ALTO, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Leone Patterson to its Board of Directors and as Chair of the Board’s Audit Committee. “We’re delighted t</description>
</item>
<item>
<title>Kalaris Announces Closing of Merger with AlloVir</title>
<link>https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-announces-closing-merger-allovir-202100406</link>
<guid isPermaLink="true">https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-announces-closing-merger-allovir-202100406</guid>
<pubDate>Tue, 18 Mar 2025 20:21:00 GMT</pubDate>
<description>Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina Currently enrolling nAMD patients in a Phase 1 trial, with initial data from Part 1 of the trial expected in the second half of 2025 Post-transaction cash of approximately $100 million expected to fund operations into the fourth quarter of 2026 Shares expected to trade on Nasdaq</description>
</item>
<item>
<title>Kalaris and AlloVir Announce Stockholder Approval of Merger</title>
<link>https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-and-allovir-announce-stockholder-approval-of-merger</link>
<guid isPermaLink="true">https://6ix.com/company/kalaris-therapeutics-inc/news/kalaris-and-allovir-announce-stockholder-approval-of-merger</guid>
<pubDate>Wed, 12 Mar 2025 04:00:00 GMT</pubDate>
<description>Combined company expected to trade on Nasdaq under “KLRS” after closing PALO ALTO, Calif. and LEXINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Kalaris</description>
</item>
<item>
<title>AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina</title>
<link>https://6ix.com/company/kalaris-therapeutics-inc/news/allovir-and-kalaris-therapeutics-announce-agreement-for-transformational-merger-to-create-company-focused-on-diseases-of-the-retina</link>
<guid isPermaLink="true">https://6ix.com/company/kalaris-therapeutics-inc/news/allovir-and-kalaris-therapeutics-announce-agreement-for-transformational-merger-to-create-company-focused-on-diseases-of-the-retina</guid>
<pubDate>Fri, 08 Nov 2024 05:00:00 GMT</pubDate>
<description>Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a novel, differentiated and</description>
</item>
<item>
<title>AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy</title>
<link>https://6ix.com/company/kalaris-therapeutics-inc/news/allovir-provides-updates-on-phase-3-clinical-development-program-for-posoleucel-an-allogeneic-virus-specific-t-cell-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/kalaris-therapeutics-inc/news/allovir-provides-updates-on-phase-3-clinical-development-program-for-posoleucel-an-allogeneic-virus-specific-t-cell-therapy</guid>
<pubDate>Fri, 22 Dec 2023 05:00:00 GMT</pubDate>
<description>Company to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to</description>
</item>
<item>
<title>AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference</title>
<link>https://6ix.com/company/kalaris-therapeutics-inc/news/allovir-to-present-at-the-piper-sandler-35th-annual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/kalaris-therapeutics-inc/news/allovir-to-present-at-the-piper-sandler-35th-annual-healthcare-conference</guid>
<pubDate>Thu, 16 Nov 2023 05:00:00 GMT</pubDate>
<description>WALTHAM, Mass.--(BUSINESS WIRE)-- AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana</description>
</item>
</channel>
</rss>